Combination therapy for myelomatosis.
Twenty-eight patients with multiple myeloma have been treated with a quadruple chemotherapeutic regimen consisting of 1, 3 bis (2-chloroethyl)-1-nitrosourea (BCNU), cyclophosphamide, melphalan, and prednisolone. Nineteen new patients and nine who had escaped from previous single-agent therapy were included in the study. The results to date, on eight criteria of response, seem to be superior to those obtained from previous chemotherapeutic regimens. The study has been in progress for 18 months and only three patients have died. Only one who had not received previous therapy died, and she had complicating hyperparathyroidism, which almost certainly contributed to her death.
D001856:Bone Marrow Examination; D002118:Calcium / Q000097:blood; D002330:Carmustine / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007128:Immunoglobulin Fragments / Q000652:urine; D007136:Immunoglobulins / Q000032:analysis; D007677:Kidney Function Tests; D008558:Melphalan / Q000008:administration & dosage* / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D009194:Myeloma Proteins / Q000032:analysis; D010954:Plasmacytoma / Q000188:drug therapy; D011239:Prednisolone / Q000008:administration & dosage* / Q000627:therapeutic use; D012709:Serum Albumin / Q000032:analysis
D006454:Hemoglobins; D007128:Immunoglobulin Fragments; D007136:Immunoglobulins; D009194:Myeloma Proteins; D012709:Serum Albumin; D003520:Cyclophosphamide; D011239:Prednisolone; D008558:Melphalan; D002118:Calcium; D002330:Carmustine